Abstract
High-grade serous ovarian carcinoma (HG-SOC) is a major cause of cancer-related death. Whether treatment order - primary debulking surgery followed by adjuvant chemotherapy (PDS) or neo-adjuvant chemotherapy with interval surgery (NACT) - affects outcome is controversial. We developed a mathematical framework that holds for hierarchical or stochastic models of tumor initiation and reproduces HG-SOC clinical course. After estimating parameter values, we infer that most patients harbor chemo-resistant HG-SOC cells at diagnosis, PDS is inherently superior to NACT due to better depletion of resistant cells, and earlier diagnosis could improve survival of primary, but not relapsed, patients. Our predictions are supported by primary clinical data from multiple cohorts. Our results have clear implications for these key issues in HG-SOC management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the Terry Fox Foundation (TFPPG 020003), National Cancer Institute (R37 49152), and Department of Defense (60167542 104703 A) (to B.G.N.), and a DCA Award from University of Toronto (to S.G.).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
All data were acquired from published clinical trials or retrospective studies.
